Amylyx Pharmaceuticals IncNASDAQ:AMLX
- LAST PRICE5.1900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.1200/ 2
- Ask / Lots5.2600/ 2
- Open / Previous Close--- / 5.1900
- Day Range---
- 52 Week Range
- Volume1,390
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMLX |
|---|---|---|
| 09:32 ET | 3922 | 5.21 |
| 09:33 ET | 1368 | 5.2501 |
| 09:35 ET | 2000 | 5.2262 |
| 09:37 ET | 2971 | 5.18 |
| 09:39 ET | 6641 | 5.1982 |
| 09:42 ET | 3297 | 5.25 |
| 09:44 ET | 800 | 5.245 |
| 09:46 ET | 13597 | 5.28 |
| 09:48 ET | 44037 | 5.275 |
| 09:50 ET | 2955 | 5.3 |
| 09:51 ET | 1448 | 5.3 |
| 09:53 ET | 38481 | 5.28 |
| 09:55 ET | 2455 | 5.22 |
| 09:57 ET | 5364 | 5.215 |
| 10:00 ET | 2911 | 5.21 |
| 10:02 ET | 1020 | 5.19 |
| 10:04 ET | 3976 | 5.16 |
| 10:06 ET | 30240 | 5.1 |
| 10:08 ET | 26520 | 5.1 |
| 10:09 ET | 4396 | 5.1136 |
| 10:11 ET | 3579 | 5.135 |
| 10:13 ET | 2620 | 5.11 |
| 10:15 ET | 2434 | 5.13 |
| 10:18 ET | 3316 | 5.17 |
| 10:20 ET | 1200 | 5.17 |
| 10:22 ET | 3546 | 5.22 |
| 10:24 ET | 1600 | 5.181 |
| 10:26 ET | 511 | 5.185 |
| 10:27 ET | 5210 | 5.17 |
| 10:29 ET | 6507 | 5.155 |
| 10:31 ET | 200 | 5.135 |
| 10:33 ET | 2595 | 5.11 |
| 10:36 ET | 2910 | 5.13 |
| 10:38 ET | 5326 | 5.12 |
| 10:40 ET | 28414 | 5.069 |
| 10:42 ET | 40742 | 5.04 |
| 10:44 ET | 38550 | 4.995 |
| 10:45 ET | 11789 | 5 |
| 10:47 ET | 8837 | 5.0702 |
| 10:49 ET | 31935 | 5.05 |
| 10:51 ET | 6790 | 5.06 |
| 10:54 ET | 15090 | 5.075 |
| 10:56 ET | 14399 | 5.09 |
| 10:58 ET | 37766 | 5.09 |
| 11:00 ET | 7980 | 5.09 |
| 11:02 ET | 2185 | 5.095 |
| 11:03 ET | 24294 | 5.01 |
| 11:05 ET | 305347 | 5.07 |
| 11:07 ET | 45271 | 5.085 |
| 11:09 ET | 1400 | 5.09 |
| 11:12 ET | 5214 | 5.15 |
| 11:14 ET | 50575 | 5.175 |
| 11:16 ET | 2200 | 5.18 |
| 11:18 ET | 3644 | 5.176 |
| 11:20 ET | 1500 | 5.16 |
| 11:21 ET | 1829 | 5.16 |
| 11:23 ET | 1584 | 5.15 |
| 11:25 ET | 800 | 5.165 |
| 11:27 ET | 800 | 5.17 |
| 11:30 ET | 4546 | 5.125 |
| 11:32 ET | 800 | 5.12 |
| 11:34 ET | 1160 | 5.11 |
| 11:36 ET | 1322 | 5.14 |
| 11:38 ET | 5333 | 5.12 |
| 11:39 ET | 800 | 5.12 |
| 11:41 ET | 800 | 5.13 |
| 11:43 ET | 1200 | 5.105 |
| 11:45 ET | 691 | 5.115 |
| 11:48 ET | 1900 | 5.12 |
| 11:50 ET | 2425 | 5.11 |
| 11:52 ET | 59588 | 5.145 |
| 11:54 ET | 1624 | 5.145 |
| 11:56 ET | 7842 | 5.15 |
| 11:57 ET | 5860 | 5.125 |
| 11:59 ET | 3347 | 5.15 |
| 12:01 ET | 1500 | 5.15 |
| 12:03 ET | 1200 | 5.15 |
| 12:06 ET | 20962 | 5.165 |
| 12:08 ET | 2263 | 5.17 |
| 12:10 ET | 2244 | 5.186 |
| 12:12 ET | 2620 | 5.22 |
| 12:14 ET | 1010 | 5.2 |
| 12:15 ET | 2500 | 5.21 |
| 12:19 ET | 15168 | 5.24 |
| 12:21 ET | 2975 | 5.24 |
| 12:24 ET | 2000 | 5.225 |
| 12:26 ET | 1900 | 5.2301 |
| 12:28 ET | 800 | 5.225 |
| 12:30 ET | 1780 | 5.235 |
| 12:32 ET | 4996 | 5.23 |
| 12:33 ET | 600 | 5.235 |
| 12:35 ET | 4000 | 5.23 |
| 12:37 ET | 200 | 5.225 |
| 12:39 ET | 800 | 5.225 |
| 12:42 ET | 1000 | 5.225 |
| 12:44 ET | 4080 | 5.24 |
| 12:46 ET | 1778 | 5.26 |
| 12:48 ET | 728 | 5.265 |
| 12:50 ET | 4400 | 5.245 |
| 12:51 ET | 300 | 5.245 |
| 12:53 ET | 1492 | 5.235 |
| 12:55 ET | 1300 | 5.235 |
| 12:57 ET | 23289 | 5.315 |
| 01:00 ET | 1100 | 5.315 |
| 01:02 ET | 3225 | 5.3388 |
| 01:04 ET | 5272 | 5.305 |
| 01:06 ET | 4698 | 5.315 |
| 01:08 ET | 3460 | 5.31 |
| 01:09 ET | 2022 | 5.32 |
| 01:11 ET | 900 | 5.336 |
| 01:13 ET | 100 | 5.33 |
| 01:15 ET | 800 | 5.3302 |
| 01:18 ET | 4439 | 5.345 |
| 01:20 ET | 2069 | 5.37 |
| 01:22 ET | 899 | 5.375 |
| 01:24 ET | 700 | 5.375 |
| 01:26 ET | 1000 | 5.39 |
| 01:27 ET | 2794 | 5.385 |
| 01:29 ET | 10936 | 5.385 |
| 01:31 ET | 2394 | 5.395 |
| 01:33 ET | 7211 | 5.415 |
| 01:36 ET | 600 | 5.405 |
| 01:38 ET | 1800 | 5.405 |
| 01:40 ET | 3234 | 5.395 |
| 01:42 ET | 4880 | 5.395 |
| 01:44 ET | 472 | 5.39 |
| 01:45 ET | 1600 | 5.385 |
| 01:47 ET | 1500 | 5.375 |
| 01:49 ET | 2700 | 5.37 |
| 01:51 ET | 200 | 5.375 |
| 01:54 ET | 2251 | 5.36 |
| 01:56 ET | 4072 | 5.355 |
| 01:58 ET | 7092 | 5.32 |
| 02:00 ET | 1477 | 5.345 |
| 02:02 ET | 1138 | 5.35 |
| 02:03 ET | 1962 | 5.34 |
| 02:05 ET | 1796 | 5.34 |
| 02:07 ET | 2578 | 5.325 |
| 02:09 ET | 2150 | 5.33 |
| 02:12 ET | 3020 | 5.315 |
| 02:16 ET | 360 | 5.315 |
| 02:18 ET | 505 | 5.315 |
| 02:20 ET | 3700 | 5.3 |
| 02:21 ET | 2704 | 5.315 |
| 02:23 ET | 4258 | 5.335 |
| 02:25 ET | 2716 | 5.345 |
| 02:30 ET | 1287 | 5.33 |
| 02:32 ET | 1400 | 5.335 |
| 02:34 ET | 2400 | 5.355 |
| 02:36 ET | 2663 | 5.335 |
| 02:38 ET | 3559 | 5.33 |
| 02:39 ET | 3207 | 5.325 |
| 02:41 ET | 7267 | 5.31 |
| 02:43 ET | 400 | 5.31 |
| 02:45 ET | 500 | 5.31 |
| 02:48 ET | 2946 | 5.31 |
| 02:50 ET | 5681 | 5.3 |
| 02:52 ET | 5026 | 5.325 |
| 02:54 ET | 7020 | 5.325 |
| 02:56 ET | 3977 | 5.315 |
| 02:57 ET | 2200 | 5.325 |
| 02:59 ET | 2442 | 5.31 |
| 03:01 ET | 1170 | 5.31 |
| 03:03 ET | 830 | 5.31 |
| 03:06 ET | 9630 | 5.305 |
| 03:08 ET | 5360 | 5.315 |
| 03:10 ET | 1700 | 5.305 |
| 03:12 ET | 5611 | 5.3048 |
| 03:14 ET | 6855 | 5.285 |
| 03:15 ET | 2042 | 5.295 |
| 03:17 ET | 800 | 5.29 |
| 03:19 ET | 1000 | 5.29 |
| 03:21 ET | 400 | 5.29 |
| 03:24 ET | 700 | 5.29 |
| 03:26 ET | 500 | 5.295 |
| 03:28 ET | 11194 | 5.285 |
| 03:30 ET | 3851 | 5.27 |
| 03:32 ET | 802 | 5.26 |
| 03:33 ET | 3200 | 5.256 |
| 03:35 ET | 10801 | 5.235 |
| 03:37 ET | 9614 | 5.24 |
| 03:39 ET | 14806 | 5.235 |
| 03:42 ET | 6511 | 5.24 |
| 03:44 ET | 4194 | 5.235 |
| 03:46 ET | 6271 | 5.235 |
| 03:48 ET | 8432 | 5.23 |
| 03:50 ET | 5042 | 5.215 |
| 03:51 ET | 7080 | 5.215 |
| 03:53 ET | 16385 | 5.245 |
| 03:55 ET | 10604 | 5.245 |
| 03:57 ET | 55381 | 5.21 |
| 04:00 ET | 170159 | 5.19 |
Nov 18, 2024
DJ Amylyx Pharmaceuticals Raised to Outperform From Neutral by Baird, from 7:36AM ET on Monday Nov 18, 2024 by Dow Jones
7:36AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 8, 2024
DJ Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 7:46AM ET on Friday Nov 08, 2024 by Dow Jones
7:46AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Press Release: Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
7:00AM ET on Thursday Nov 07, 2024 by Dow JonesAmylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 4, 2024
Press Release: Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024, from 9:04AM ET on Monday Nov 04, 2024 by Dow Jones
9:04AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amylyx Pharmaceuticals Inc | 355.8M | -1.4x | --- |
Organogenesis Holdings Inc | 533.0M | -70.9x | --- |
Ironwood Pharmaceuticals Inc | 534.5M | -208.5x | --- |
Amarin Corporation PLC | 215.9M | -5.5x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Ginkgo Bioworks Holdings Inc | 378.8M | -0.5x | --- |
Company Information
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Contact Information
- Headquarters
- 43 THORNDIKE STREETCAMBRIDGE, MA, United States 02141
- Phone
- 617-682-0917
- Fax
- 302-636-5454
Executives
- Chair of the Board of Directors
- George Milne
- Co-Chief Executive Officer, Director
- Joshua Cohen
- Co-Chief Executive Officer, Director
- Justin Klee
- Chief Financial Officer
- James Frates
- Chief Legal Officer and General Counsel
- Gina Mazzariello
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $355.8M |
|---|---|
Revenue (TTM) | $196.5M |
Shares Outstanding | 68.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.82 |
Book Value | $6.40 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 1.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -138.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
